Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 1 completion115d agoBeijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)pneumococcal (20-valent) vaccine

Therapy area: Respiratory. Indication: Streptococcal Pneumonia

full page →pneumococcal (20-valent) vaccine →source: globaldata

Apr 30, 2026phase 1 completion115d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

Therapy area: Immunology. Indication: Inflammation

full page →FT-2109 →source: globaldata

Apr 30, 2026phase 1 completion115d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

Therapy area: Immunology. Indication: Inflammation

full page →FT-2109 →source: globaldata

Apr 30, 2026phase 1 completion115d agoInsignis Therapeutics Inc — HLK-0006 (Phase I Trial Completion)HLK-0006

Therapy area: Immunology. Indication: Anaphylaxis, Food Allergy, Peanut Allergy

full page →HLK-0006 →source: globaldata

Apr 30, 2026phase 1 initiation115d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

full page →IASO-782 →source: globaldata

Apr 30, 2026phase 1 2 completion115d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

full page →M-701 →source: globaldata

Apr 30, 2026phase 2 completion115d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →UA-021 →source: globaldata

Apr 30, 2026phase 2 completion115d agoUniversity of Benin Teaching Hospital — doxycycline (Phase II Trial Completion)doxycycline ER

Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

full page →doxycycline ER →source: globaldata

Apr 30, 2026phase 2 completion115d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →telitacicept →source: globaldata

Apr 30, 2026phase 2 completion115d agoNational Health and Medical Research Council — docosahexaenoic acid (Phase II Trial Completion)docosahexaenoic acid

Therapy area: Women's Health. Indication: Labor And Delivery

full page →docosahexaenoic acid →source: globaldata

Apr 30, 2026phase 2 completion115d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

full page →autologous regulatory T cells →source: globaldata

Apr 30, 2026phase 2 completion115d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

full page →dupilumab →source: globaldata

Apr 30, 2026phase 2 completion115d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

full page →tulisokibart →source: globaldata

Apr 30, 2026phase 2 completion115d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion115d agoTaian City Central Hospital — alfentanil (Phase II Trial Completion)alfentanil

Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

full page →alfentanil →source: globaldata

Apr 30, 2026phase 2 completion115d agoCentrum Clinic IVF Center — follitropin (Phase II Trial Completion)follitropin

Therapy area: Women's Health. Indication: Female Infertility

full page →follitropin →source: globaldata

Apr 30, 2026phase 2 completion115d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

full page →tozorakimab →source: globaldata

Apr 30, 2026phase 2 completion115d agoRenji Hospital — norepinephrine (Phase II Trial Completion)norepinephrine

Therapy area: Genito Urinary System, Immunology. Indication: Delayed Graft Function (DGF), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

full page →norepinephrine →source: globaldata

Apr 30, 2026phase 2 completion115d agoFirst Affiliated Hospital of Kunming Medical University — sugammadex (Phase II Trial Completion)sugammadex

Therapy area: Non Malignant Disorders, Women's Health. Indication: Unspecified Gynecological Disorders, Uterine Leiomyoma (Uterine Fibroids)

full page →sugammadex →source: globaldata

Apr 30, 2026phase 2 completion115d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

Therapy area: Immunology. Indication: Inflammation

full page →SSJG-009 →source: globaldata

Apr 30, 2026phase 2 completion115d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

Therapy area: Respiratory. Indication: Cough

full page →LIDOCAINE →source: globaldata

Apr 30, 2026phase 2 completion115d agoPolice General Hospital — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

full page →acetaminophen ER →source: globaldata

← prev

page 2 of 2

Week of Apr 27, 2026